Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High Risk Prostate Cancer - Protocol 2
This study will explore the combination of a stereotactic body radiation therapy (SBRT)
approach combined with one year of luteinizing hormone releasing hormone (LHRH) agonist for
older men with high risk prostate cancer, or men unwilling to undertake conventionally
fractionated therapy and three years of adjuvant hormone therapy.
The purpose of this study is to examine the safety of a shorter course of radiation
treatment combined wtih androgen deprivation therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society